{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:52:27Z","timestamp":1769075547978,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.canrad.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T08:17:26Z","timestamp":1559722646000},"page":"423-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus"],"prefix":"10.1016","volume":"23","author":[{"given":"A.","family":"Visy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Racadot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2019.01.005_bib0075","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.canrad.2019.01.005_bib0080","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","article-title":"Radiation recall with anticancer agents","volume":"15","author":"Burris","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2019.01.005_bib0085","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1200\/JCO.2012.47.7455","article-title":"Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months","volume":"31","author":"Straka","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.01.005_bib0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","article-title":"Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial","volume":"9","author":"Kao","year":"2014","journal-title":"Target Oncol"},{"key":"10.1016\/j.canrad.2019.01.005_bib0095","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1078-0432.CCR-07-0955","article-title":"Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer","volume":"14","author":"Manegold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2019.01.005_bib0100","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s10637-010-9613-1","article-title":"Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy","volume":"30","author":"Kirova","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.canrad.2019.01.005_bib0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00280-016-3064-0","article-title":"A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I","volume":"78","author":"De Melo","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.canrad.2019.01.005_bib0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.canrad.2014.04.007","article-title":"[Concurrent association of reirradiation therapy with everolimus for lymph node metastasis of gastroesophageal junction cancer: a case report]","volume":"18","author":"Pernin","year":"2014","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.01.005_bib0115","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdv105","article-title":"Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer","volume":"26","author":"Deutsch","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2019.01.005_bib0120","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.ejca.2012.12.009","article-title":"Targeted therapy-induced radiation recall","volume":"49","author":"L\u00e9vy","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2019.01.005_bib0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2014.08.030","article-title":"Radiation-recall dermatitis with the everolimus\/exemestane combination ten years after adjuvant whole-breast radiotherapy","volume":"112","author":"Ioannidis","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.01.005_bib0130","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000353309","article-title":"Radiation-induced esophagitis exacerbated by everolimus","volume":"6","author":"Miura","year":"2013","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.canrad.2019.01.005_bib0135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/annonc\/mdq741","article-title":"Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?","volume":"22","author":"Bourgier","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2019.01.005_bib0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3727\/096504015X14400775740416","article-title":"Radiation recall pneumonitis during systemic treatment with everolimus","volume":"22","author":"Clark","year":"2014","journal-title":"Oncol Res"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S127832181930099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S127832181930099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:30:36Z","timestamp":1761136236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S127832181930099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S127832181930099X"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2019.01.005","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}